ASCO Publications

🌟🟠 HER2 in mCRC
New pooled analysis in JCO
(8 RCTs, n=1,604)🌟

✅ HER2+ = worse PFS & OS
❌ Not predictive for Bev vs anti-EGFR
➡️ Prognostic, not predictive

#GIOnc #ColorectalCancer #mCRC #HER2 #Oncology #JCO #Medicalwatch

ascopubs.org/doi/10.1200/...

🔬 Conclusion: Perioperative Durvalumab in MIBC = clinically effective + socioeconomically justified

#BladderCancer #GUcancer #OncoTwitter #Immunotherapy #HealthEconomics #Medicalwatch 🚀

www.ejcancer.com/article/S095...

Prognosis and biological characteristics of ER-low metastatic breast cancer: results from a multicenter cohort and the TONIC trial. Abstract. Purpose: To assess prognosis of ER-low expression and its dynamics in HER2- metastatic breast cancer (BC) and to compare sensitivity to nivolumab between ER-low and triple-negative (TN) BC. ...

🎯 Clinical impact: ER-low BC should be managed more like TNBC, with inclusion in immunotherapy & ADC trials. Re-biopsy at relapse is crucial to detect phenotype switch.

#BreastCancer #ERlow #TNBC #Immunotherapy #Medicalwatch
aacrjournals.org/clincancerre...

Geriatric Assessment: ASCO Global Guideline | JCO Global Oncology ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO Guidelines Methodology Manual, ASCO Guidelines follow ...

✅ Barriers: resource gaps, training, access in LMICs

➡️ Clinical practice impact: GA should be mandatory in global oncology to optimize outcomes for older adults.

#GeriatricOncology #ASCO #OncoTwitter #Medicalwatch #CancerCare #GlobalOncology
ascopubs.org/doi/10.1200/...

FGFR1-amplified colorectal cancer: a distinct prognostic subtype identified through integrated genomic and immunohistochemical profiling Fibroblast growth factor receptor (FGFR) alterations are established therapeutic targets in cholangiocarcinoma and urothelial carcinoma but remain understudied in colorectal cancer (CRC). This study i...

💡 Clinical Tip: FGFR1 amplification defines a high-risk CRC subset. IRS-based IHC scoring may serve as practical biomarker to identify candidates for novel FGFR1-targeted strategies.

#ColorectalCancer #FGFR1 #Biomarkers #PrecisionOncology #OncoTwitter #Medicalwatch
www.esmoopen.com/article/S205...

Geriatric Assessment: ASCO Global Guideline | JCO Global Oncology ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO G...

#GeriOncology #ASCOGuideline #GlobalOnc #CancerCare #OncoTwitter #Medicalwatch
ascopubs.org/doi/pdf/10.1...

Inferior control arms in oncology trials in LMICs: contextualised or compromised? In recent years, cancer drug randomised controlled trials (RCTs) have been criticised for employing a control arm treatment that is inferior or suboptimal to the existing standard of care.1 2 Using an...

✅ Highlights the urgent need for equity & global trial harmonization.

❓ Question to think: Should trial standards always reflect the best global care — or adapt to local realities?

#OncoEthics #GlobalOncology #ClinicalTrials #OncoTwitter #Medicalwatch
bmjoncology.bmj.com/content/4/1/...

💡 Clinical Tip: In MBC (esp. HER2+ & TNBC), discuss brain metastasis risk proactively — patient-centered dialogue is key while awaiting trial evidence.
#BreastCancer #BrainMets #MetastaticBC #OncoTwitter #MedicalWatch

Artificial intelligence across the cancer care continuum This review highlights the expanding role of artificial intelligence across the cancer care continuum, from risk prediction to end-of-life care. It emphasizes both the promise of artificial intellige...

🔮 Future: digital twins, living evidence pipelines & multimodal decision-support at point of care
#AI #Oncology #CancerCare #DigitalHealth #OncoTwitter #MedicalWatch
acsjournals.onlinelibrary.wiley.com/doi/10.1002/...

IMvigor011 Bladder Cancer Trial Achieves Positive Results, with Signatera™ Strongly Predicting Adjuvant Immunotherapy Benefit Topline results from the trial show that Signatera-positive patients treated with atezolizumab (Tecentriq®) had statistically significant and clinically meaningful improvements in disease-free surviva...

✅ 1st Phase III showing MRD (ctDNA)-guided approach in bladder cancer
➡️ Clinical Tip: ctDNA MRD may personalize care & spare low-risk pts from overtreatment.

#BladderCancer #OncoUrology #Immunotherapy #ctDNA #IMvigor011 #Medicalwatch

natera.com/company/news...

Treatment of NSCLC after chemoimmunotherapy — are we making headway? - Nature Reviews Clinical Oncology Immune-checkpoint inhibitors have dramatically improved the outcomes in patients with advanced-stage driver-negative non-small-cell lung cancer (NSCLC), although most patients will ultimately have dis...

💡 Take-home message: Restoring antitumor immunity via multimodal, biomarker-guided strategies is the next frontier in post-ICI NSCLC.

#LungCancer #NSCLC #ImmunoOncology #CheckpointInhibitors #Medicalwatch
www.nature.com/articles/s41...

Outcomes of subsequent treatment regimens after trastuzumab deruxtecan in patients with metastatic breast cancer AbstractBackground. Most patients with metastatic breast cancer (MBC) are eligible for treatment with trastuzumab deruxtecan (T-DXd). No data are available

#BreastCancer #HER2 #T-DXd #SacituzumabGovitecan #OncoTwitter #MedicalWatch #MBC
academic.oup.com/jnci/advance...

Medical Watch for Seniors: Help at the Touch of a Button Why Seniors Need a Medical Watch There is no denying that aging presents its own set of challenges, but fortunately for seniors, technology has made staying independent...

With MedAlertCare, seniors can enjoy greater independence while loved ones gain peace of mind knowing help is always within reach. 🏡🚶‍♂️

www.easyfie.com/read-blog/23...

#SeniorSafety #MedicalWatch #FallDetection #HealthTech #IndependentLiving #ElderCare #SmartTech #AgingInPlace